A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessment by Roccatello, Dario et al.
This full text was downloaded from iris - AperTO: https://iris.unito.it/
iris - AperTO
University of Turin’s Institutional Research Information System and Open Access Institutional Repository
This Accepted Author Manuscript (AAM) is copyrighted and published by Elsevier. It is
posted here by agreement between Elsevier and the University of Turin. Changes resulting
from the publishing process - such as editing, corrections, structural formatting, and other
quality control mechanisms - may not be reflected in this version of the text. The definitive
version of the text was subsequently published in AUTOIMMUNITY REVIEWS, None,
2015, 10.1016/j.autrev.2015.07.017.
You may download, copy and otherwise use the AAM for non-commercial purposes
provided that your license is limited by the following restrictions:
(1) You may use this AAM for non-commercial purposes only under the terms of the
CC-BY-NC-ND license.
(2) The integrity of the work and identification of the author, copyright owner, and
publisher must be preserved in any copy.
(3) You must attribute this AAM in the following format: Creative Commons BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en),
10.1016/j.autrev.2015.07.017
The publisher's version is available at:
http://linkinghub.elsevier.com/retrieve/pii/S1568997215001664
When citing, please refer to the published version.
Link to this full text:
http://hdl.handle.net/2318/1545463
A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion 
without immunosuppressive maintenance treatment—Clinical response compared to literature and 
immunological re-assessment 
Dario Roccatelloa, b, Savino Sciasciaa, Simone Baldovinoa, Daniela Rossia, Mirella Alpaa, Carla Narettoa, 
Debora Di Simonea, Matteo Simoncinia, Elisa Menegattia 
a Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Center of Research of 
Immunopathology and Rare Diseases–Coordinating Center of Piemonte and Valle d'Aosta Network for Rare 
Diseases, Turin, Italy 
b SCDU Nephrology and Dialysis, S. Giovanni Bosco Hospital, Turin, Italy 
Abstract 
Background 
B cells (BC) play a critical role in systemic lupus erythematosus (SLE). BC depletion therapy still remains an 
attractive option, despite the disappointing results of randomized controlled trials (RTCs). 
Methods 
Twelve patients with SLE [3 males, mean age 43.8 yrs (25–55)] with severe multiorgan involvement all 
including kidney (3 patients with Class IV, 4 with Class III/V and 5 with Class V, according to the 
International Society of Nephrology/Renal Pathology Society glomerulonephritis classification), skin lesions 
[10], severe polyarthralgias with arthritis [10], polyserositis [2], and lymphadenopathy [5] have been 
prospectively treated with an intensified B cell depletion therapy (IBCDT) protocol due to their resistance or 
intolerance to previous therapy (six cases) or as a front line immunosuppressive treatment in 6 women 
with unsatisfactory therapeutic compliance or as a specific request of a short-time immunosuppression for 
gestational perspectives. Protocol: Rituximab (RTX) 375 mg/sm on days 1, 8, 15, 22, and 2 more doses after 
1 and 2 months, associated with 2 IV administrations of 10 mg/kg of cyclophosphamide and 3 
methylprednisolone pulses (15 mg/kg) followed by oral prednisone (0.8 mg/kg/day, rapidly tapered to 5 
mg/day by the end of the 3rd month after RTX). No further immunosuppressive maintenance therapy has 
been given. 
Results 
Patients had been followed-up for a mean of 44.5 (24–93) months. Significant decreases (p < 0.05) were 
found in the levels of ESR (baseline mean value: 55.0 mm; 3 months: 36; end of follow-up: 13), anti-dsDNA 
antibodies (baseline: 185 U; 3 months: 107; end of follow-up: 15), and proteinuria (baseline: 4.9 g/24 h; 3 
months: 0.97; end of follow-up: 0.22). C4 values (baseline 11 mg/dl) significantly increased (p < 0.05) after 3 
months (22 mg/dl) and at the end of the follow-up (20 mg/dl). Of the 12 patients, 9 (75%) have remained 
well after one cycle of IBCDT, with no flare (mean 51.6 months [25–93]). Three patients relapsed after 36, 
41, and 72 months, respectively. Following re-treatment, they again showed complete remission over 18–
48 months of observation. 
Conclusions 
A promising role of RTX in an intensified protocol of induction therapy can be envisaged in patients for 
whom avoiding immunosuppressive maintenance therapy and sparing steroids are particularly appealing. 
Moreover, our data confirm in one of the longest follow-up available, the opportunity to reconsider the 
regimens of BL depletion in the treatment of the most severe or refractory forms of SLE despite the 
disappointing results of RCTs. 
 
Abbreviations 
RTX, rituximab; IS, immunosuppression; GC, glucocorticoid; F/U, follow-up; PCS, prospective color study; 
RCS, retrospective cohort study; CR, complete remission; PR, partial remission; LN, lupus nephritis; NM, not 
mentioned; CYC, cyclophosphamide; RCT, randomized controlled trials; MTP, methylprednisolone; AZA, 
azathioprine; MMP, mycophenolate; Cys, cyclosporine; UTI, urinary tract infection 
 
1.Introduction 
B cells are thought to play an important role in the pathogenesis of systemic lupus erythematosus (SLE) [1] 
and [2]. B cell depletion therapy (BCDT), based on rituximab (RTX), a chimeric monoclonal antibody specific 
for CD20, has proved to be promising in the treatment of patients with SLE [3] and other autoimmune 
conditions [4], [5], [6], [7], [8], [9] and [10]. We have previously published the favorable outcome of 8 
patients with severe SLE treated with an intensive short-term treatment with RTX, cyclophosphamide, and 
methylprednisolone pulses [11]. Our approach was able to avoid further immunosuppressive maintenance 
therapy [12]. 
BCDT is generally well tolerated, but its long-term safety profile is still debatable as most studies have 
follow-up data of less than 1 year. 
We are now reporting on the very long-term outcome of 12 prospectively enrolled patients with renal 
involvement SLE (the original cohort plus an additional 7 patients) treated with the intensified BCDT (IBCDT) 
at our center. 
Additionally, the observed results were compared to those emerging from the updated reviews of the 
literature on this topic focusing on study with a minimum follow-up of 24 months. 
 
2. Methods 
2.1. Patients 
Twelve patients, nine women and three males, mean age 43.8 years (range 25–55 years), with severe 
multiorgan involvement, including kidney (3 patients with Class IV, including a case of rapidly progressive 
glomerulonephritis, with 60% of florid crescents), 4 with Class III/V and 5 with Class V Lupus Nephritis (LN) 
according to the International Society of Nephrology/Renal Pathology Society Glomerulonephritis 
Classification), skin lesions [10 patients], severe polyarthralgias with arthritis [10], polyserositis [2], and 
lymphadenopathy [5], were considered eligible for RTX therapy due to their resistance or intolerance to 
previous therapy (6 cases) or as a front line treatment in 6 women with unreliable therapeutic compliance 
or gestational perspectives. 
In non-naïve patients, prior immunosuppressive therapy included methylprednisolone pulses and oral 
steroids (all 6 previously treated patients), I.V. cyclophosphamide (2 patients), and both intravenously and 
orally administered cyclophosphamide for a cumulative dose of 9 g in one patient, azathioprine in 2 
patients, mycophenolate mofetil in 2 patients, cyclosporine A in four cases, hydroxychloroquine in all 6 
previously treated cases, and thalidomide in 1 patient. 
RTX was administered intravenously as previously described [11] at a dose of 375 mg/m2 on days 2, 8, 15, 
and 22. Two more doses were administered 1 and 2 months following the last weekly infusion. This 
treatment was combined with two pulses of 10 mg/kg cyclophosphamide (days 4 and 17) and three 
intravenous pulses of 15 mg/kg (days 1, 4, and 8) methylprednisolone followed by oral prednisone, 0.8 
mg/kg/day for 2 weeks rapidly tapered until 5 mg in 3 months. 
Response was evaluated by assessing the changes in clinical signs and symptoms and laboratory 
parameters. SLEDAI score was separately assessed by two investigators (S.S. and M.A.). 
 
Circulating B cells in the peripheral blood were investigated by detection of CD20+ B cells and analyzed by 
flow cytometry at baseline, month 1, month 2, and every other month thereafter. 
We examined changes in T cell homeostasis following rituximab-induced B cell depletion in two patients. 
Analysis included flow cytometry studies at baseline (before the first RTX infusion), at months 3, 6, and 9. 
Whole blood samples obtained in the morning, in EDTA, were stained with monoclonal antibodies against 
CD45 (APC 100 eBioscience Bender Medsystems, CA, USA), CD3 (FITC eBioscience Bender Medsystems, CA, 
USA), CD4 (PC7 Beckman Coulter, CA, USA), CD19 (Pacific Blue™, Beckman Coulter, CA, USA), CD20 (PE 
Beckman Coulter, CA, USA), and CD25 (PerCP-eFluor 710 eBioscience/Bender Medsystems, CA, USA), 
FOXP3 (PE Staining set, eBioscience Bender Medsystems, CA, USA). 
 
2.2. Renal response and relapse 
For the evaluation of the renal response, the Joint European League Against Rheumatism and European 
Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) consensus statement 
was used [13]. 
In detail, a complete renal response (CR) has been defined as proteinuria < 0.5 g/24 h and normal or near-
normal (within 10% of normal GFR if previously abnormal) GFR and, additionally, negative anti-DNA 
antibodies and normal levels of C3 and C4. Partial response (PR) has been defined as ≥ 50% reduction in 
proteinuria to subnephrotic levels and normal or near-normal GFR. 
The definition of renal flares included a reproducible increase of serum creatinine by ≥ 30% (or decrease in 
GFR by ≥ 10%) and/or an increase of proteinuria > 0.5 g/24 h if CR was initially achieved, or ≥ 50% in cases 
of PR. 
 
2.3. Statistics 
For comparison of variables at baseline and follow-up, Student's t-test was used for normally distributed 
parameters and the non-parametric Mann–Whitney test for non-normally distributed parameters. 
Correlations were calculated and significance determined by Fisher's test. Multivariable logistic regression 
analysis was used to identify any independent predictors of flare. Kaplan–Meier hazard plots were 
constructed for time to time to renal flare. For these analyses, with the Prism (GraphPad Software, CA, 
USA) and SPSS (IBM Corporation, NY, USA) software programs was used. p < 0.05 was considered 
significant. 
This study was performed according to the local rules of off-label therapy in Piedmont Region (Northwest 
Italy). 
 
3. Comparison with previously published literature 
3.1. Selection of trials 
We searched MEDLINE and EMBASE using the terms “rituximab” and “systemic lupus erythematosus” 
published from January 1, 2002, to May 24, 2015. Studies were included if they were randomized 
controlled studies or case series with more than 10 adult patients focused on renal clinical outcomes. 
Studies were excluded (1) if they were reviews or expert comments or case series with fewer than 10 
patients or pediatric cases, (2) if the main outcome was not clinical, and (3) if they were published only in 
abstract form. 
When several publications under the same group of patients were found, only the most recent and 
comprehensive paper was considered, unless the publication was derived from another patient cohort. 
Among the 651 sorted publications, 15 studies met the inclusion criteria, with 14 open-label trials on LN 
[14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26] and [27] and one randomized controlled 
trial [28]. For each paper, selected items were systematically searched for: number of included patients, 
follow-up, indication for treatment with RTX and dosage, concomitant immunosuppressive treatment, 
corticosteroid dosage, and clinical and biological outcomes. 
 
4. Results 
4.1. Our cohort 
The mean duration of disease and follow-up after IBCDT was 13 years (range 3–24 years) and 44.5 months 
(range 24–93 months), respectively. 
Following IBCDT, significant decreases (p < 0.05) were found in the ESR levels (baseline mean value: 55.0 
mm; 3 months: 36 mm; end of follow-up: 13 mm), anti-dsDNA antibodies (baseline: 185 U; 3 months: 107 U 
; end of follow-up: 15 U), and proteinuria (baseline: 4.9 g/24 h; 3 months: 0.97 g/24 h; end of follow-up: 
0.22 g/24 h). Conversely, C4 values (baseline 11 mg/dl) significantly increased (p < 0.05) after 3 months (22 
mg/dl) and at the end of follow-up (20 mg/dl) ( Fig. 1 and Fig. 2). Mean serum creatinine values were 0.89 
mg/dl (0.6–2.6) at baseline, 0.87 (0.6–1.7) after 3 months and 0.83 mg/dl (0.6–1.1) at end of follow-up. 
IBCDT resulted in a decrease of median global SLEDAI from 16.5 [12], [13], [14], [15], [16], [17], [18], [19], 
[20], [21], [22], [23], [24], [25], [26] and [27] to 4 [1], [2], [3], [4] and [5] at 12 months (p < 0.001) (Fig. 3A). 
Constitutional symptoms, including arthralgia, weakness, and fever, disappeared in all the previously 
affected patients, while serositis and skin lesions gradually resolved. 
All patients had complete peripheral blood-B cell depletion. The CD20+ B cells were detectable in the 
circulation after a mean of 14.5 months (12–19 months) (Fig. 3B). Of note, at 36 months, CD20 cell number 
was still lower than baseline (p < 0.01). 
Patients were not given any further immunosuppressive maintenance therapy during the follow-up, and 
oral prednisone was tapered to 5 mg/day by the end of the 3rd month after RTX. 
Nine out of 12 patients (75%) remained in remission after one cycle of IBCDT, with no flare (mean 51.6 
months [25–93]) (Fig. 4). Three patients relapsed after 36, 42, and 72 months, respectively. Following re-
treatment, they again showed complete remission over 18–48 months of observation. 
No serious adverse events were reported (2 cases of infusion speed-related bradycardia). Of note, no 
severe infections were observed during the follow-up. 
In 5 patients achieving a CR within the first 6 months, a significant longer time to repopulation of B cells in 
the circulation was noted (p = 0.05) compared with the 7 patients who achieved CR later. 
As shown in Fig. 5, upon detection of B cell depletion, we observed in 9 months a 3.5-fold increase the 
circulating Treg (CD4+CD25+FOXP3+). 
 
5. Published literature 
5.1. Open studies 
Fourteen open-label trials [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26] and [27] on 
patients with LN met our inclusion criteria (Table 1). All used renal biological values as criteria to assess 
clinical outcome with the definition of complete response (CR) and partial response (PR) detailed in Table 2. 
A more detailed analysis has been done on 4 prospective case series with more than 24 months of follow-
up [18], [24], [25] and [26] (in bold in the Table 1). These trials included patients mostly with active LN 
despite treatment (World Health Organization or International Society of Nephrology/Renal Pathology 
Association class III (20 patients), IV (46 patients), III-V (4 patients), and IV-V (4 patients)). Thirty-three 
patients had class V LN. Patients received variable doses of RTX (2 × 1 g 4 × 375 mg/m2), and 
immunosuppressant agents were continued, as detailed in Table 1. 
 
 
 
5.2. Randomized controlled trial 
The Lupus Nephritis Assessment with Rituximab (LUNAR) trial included patients with new or relapsed class 
III or IV (± class V) LN, supported by a renal biopsy [28]. Patients were randomized 1:1 to receive placebo or 
RTX 2 × 1 g repeated 6 months apart in conjunction with MMF and oral prednisone. Other 
immunosuppressive agents were stopped. Response criteria are detailed in Table 2. Among the 144 
patients enrolled (72 patients in each group), global renal response rates (CR/PR) at week 52 were not 
statistically different between the RTX and the placebo groups (placebo group: CR 30.6%, PR 15.3%; and 
RTX group: CR 26.4%, PR 30.6%). 
 
6. Discussion 
The results of our study show that IBCDT can be a therapeutic option for patients with LN, with a favorable 
very long-term safety and efficacy profile. Seventy-five percent of patients remained in remission after one 
cycle of IBCDT without any further immunosuppressive maintenance treatment and did not relapse. These 
data confirm our previous results in case of refractory SLE [11]. The main interest of these findings resides 
in the relatively short time of standard immunosuppression, which strongly limits the possible adverse 
effects of steroids and cyclophosphamide assuring a long-lasting remission without immunosuppressive 
maintenance therapy [12]. Besides, this scheme might also be useful in low-compliance patients and avoid 
prolonged hospitalization. 
When comparing to the available literature, we retrieved 4 open studies with clearly reported outcomes 
that included at least 10 patients and had a follow-up period of at least 24 months (mean 43.75 months). 
The overall response rate (including complete and partial responses) ranged from 72% to 90% (median 
84%), the complete response rate from 61% to 72% (median 67%) (Fig. 6). 
In our study, we observed an overall 100% of renal response albeit with a 25% rate of relapse meanly after 
50 months of symptom-free period without urinary abnormalities (Fig. 6). 
 
The following points should be considered. 
First, in the mentioned studies [18], [24], [25] and [26], RTX has been used either as two doses of 1,000 mg 
given 2 weeks apart (two-dose regime, commonly used in RA) or as four doses of 375 mg/m2 (four dose 
regime, most common regime used in lymphoma) given 1 week apart. Our scheme included two more 
doses administered 1 and 2 months following the last 375 mg/m2 weekly infusion (so called “4 plus 2” 
scheme). This represents a novelty of this open single-center study and confirms our observations in other 
immune-mediated diseases [29], [30], [31], [32] and [33]. Notably, a systematic review of the clinical 
experience of RTX for the treatment of refractory SLE suggests that the lymphoma regimen may be more 
effective in achieving an improvement than the two doses regimen [34]. Besides, in our cohort, a delay in 
repopulation was found to increase the likelihood of achieving a CR within the 6 months. This observation 
would support the choice of a treatment-to-target approach to achieve an adequate degree of B cell 
depletion and a clinical response in LN. Several research groups have noted that the degree of B cell 
depletion is variable in SLE, but early repopulation is common in patients with a poor response to RTX [35]. 
The underlying reasons for the variability in B cell depletion remain elusive [7], [36], [37] and [38]. A 
polymorphism in Fcγ receptor IIIa has been shown to be important in achieving an adequate degree of B 
cell depletion, in favor of the high-affinity genotypes Fcγ receptor IIIa V158F (V, valine; F, phenylalanine) 
[39]. 
An IBCDT would therefore seem a rational approach, also taking into account that information derived from 
mouse models suggests that B cells exert their pathogenic role not only by producing auto-antibodies and 
regulating their specificities, but also by regulating the function of auto-reactive T cells, influencing antigen-
presenting cells, and producing cytokines. Regulatory T cells (Treg) are critically involved in the 
pathogenesis of autoimmune diseases by suppressing effector T cells proliferation and cytokine production 
[40] and [41]. Interestingly, Treg frequencies have been previously shown to increase in the blood of 
patients with SLE following RTX [42]. In our study, in a sub-cohort of IBCDT-treated patients with LN, we 
noticed that, at the onset of B cell depletion, patients displayed sharp increases in CD4+CD25+FOXP3+ cells 
in the peripheral blood. We hypothesized that a subset of these cells might represent expanded regulatory 
T cells (Treg), considered to be essential in the maintenance of peripheral self-tolerance [41]. This could be 
a secondary consequence of clinical remission, or, if Treg are actually associated with the disease process, 
these data might imply that Treg are in some way B cell dependent. 
Besides, as previously emphasized [43] and [44], the possible synergistic effect of RTX in combination with 
cyclophosphamide could not be excluded in maintaining a sustained B cells depletion. 
Second, albeit in our cohort a significant decrease of proteinuria and markers of activity has been observed 
since month 3, the time to CR was longer in most of the cases and documented within 12 months of follow-
up. These data suggest that the efficacy of RTX has to be evaluated over longer follow-up periods in order 
to increase the likelihood of capturing complete responders in the differentiation between active treatment 
and comparators. This observation may be in line with the fact that the Lupus Nephritis Assessment with 
Rituximab (LUNAR) clinical trial, investigating the efficacy of RTX in patients with LN in a double-blind, 
randomized trial, failed to achieve its primary endpoint assessed at week 52, although the serological 
improvement was statistically better in the RTX group [28]. A further consideration is worthy of note in the 
contest of LUNAR. One-hundred-forty-four patients from 55 centers were enrolled, resulting in a mean of 
2.62 patients for each center. Such heterogeneity might have significantly influenced the results of the trial. 
Third, a further interest of our regimen resides in the relatively short time of standard immunosuppression 
associated with a noticeable steroid sparing effect. Since the end of the third month of therapy, patients 
were given 5 mg prednisone. When compared to other studies with similar follow-up (bold references in 
Table 1), we observed a significantly lower rate of adverse events, especially in regard to severe infections 
(which did not occur in our cohort). The fact that RTX was not shown to be superior to conventional 
therapy in the LUNAR trial does not necessarily signify that it is inferior, mainly because its safety profile 
seems to be better than standard immunosuppression. 
 
6.1. Limitations of the study 
The main limitations of our study are the open non-blinded nature and the limited number of enrolled 
subjects. However, those are counterbalanced by the facts that our data are supported by a very long-term 
follow-up in a cohort of real-life SLE patients and that IBCDT allows a relatively short time of standard 
immunosuppression associated with a marked steroid sparing effect. 
 
7. Conclusions 
This prospective study brings additional long-term evidence of a role of RTX as an off-label agent in cases of 
LN who are intolerant or resistant to conventional therapy and need alternative therapeutic options or in 
patients with specific request of a short-time immunosuppression (e.g., with gestational perspectives). 
IBCDT obtained a long-lasting remission, which was maintained with minimal doses of prednisone by the 
end of the third month of therapy, avoiding the need of prolonged immunosuppression and minimizing the 
destructive effects of steroids. IBCDT could represent a valid alternative to offer patients treatments 
tailored to the individual needs based on the severity of the disease, previous medical history, or desire to 
have children and at same time minimizing the risk of adverse effects. 
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Fig. 1.  
Serologic profile of the SLE patients treated with In. Anti-DNA antibodies, erythrocytes sedimentation rate (ESR), and 
C4 were evaluated at 0, 3, 6, at 12 months and then yearly. 
*p < 0.05; **p < 0.01. 
 
 
 
 
 
 
 
 
Fig. 2.  
Proteinuria levels are shown. Proteinuria significantly improved since month 3 after intensified B cell depletion 
therapy protocol. Values are shown as mean ± SEM. ***p < 0.001. 
 
 
 
 
Fig. 3.  
(A) SLEDAI values are shown at baseline and 12 months after intensified B cell depletion therapy protocol. 
(B) Total numbers of CD20 + cells (B cells) in SLE patients before and after treatment with rituximab. 
 
 
 
 
 
 
 
 
 
Fig. 5.  
Representative dot-plots of TReg (CD4+CD25+FOXP3+, upper plots) and B cell (CD 20+, lower plots) as evaluated by 
flow cytometry. Samples from a responder without relapse, were analyzed before and 3, 6, and 9 months after the 
intensified B cell depletion therapy. 
At 1 month, upon detection of B cell depletion, the patient sample showed an increase of the percentage of 
TReg compared with baseline. 
Of note, a 3.5-fold increase of the circulating Treg (CD4+CD25+FOXP3+) has been observed over 9 months. 
 
 
 
Fig. 6.  
Rates of complete (CR) and partial responses (PR) and no response (NR) to RTX in patients with lupus nephritis. We 
retrieved 4 studies with clearly reported outcomes that included at least 10 patients and had a follow-up period of at 
least 24 months (mean 43.75 months). We compared these results to our data. The overall response rate (including 
complete and partial responses) ranged from 72% to 100% (median 88%), the complete response rate from 61% to 
100% (median 70%). The flare rate (FR) ranged from 10% to 28% (median 24.4%). Renal responses are characterized 
as decreased proteinuria, improved kidney function, and decreased expression of serological markers of disease 
activity, in parallel with improved clinical measures. 
 
 
 
 
Table 1 Study characteristics and clinical outcome of rituximab-treated patients in lupus nephritis trials. 
 
Studies with more than 24 months of follow-up are marked in bold. 
 
 
 
Table 2 Definitions of complete and partial responses in lupus nephritis trials 
 
a Additionally, CR definition includes negative anti-DNA antibodies and normal levels of C3 and C4. 
 
 
